Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

129P - Adjuvant therapy for T3 non-small cell lung cancer with additional intrapulmonary nodules


31 Mar 2023


Poster Display session


Arvind Kumar


Journal of Thoracic Oncology (2023) 18 (4S): S106-S115.


A. Kumar1, R. Choudhary2, A. Potter3, C. Mathey-Andrews2, P. Ugalde4, L. Martin5, C.J. Yang2

Author affiliations

  • 1 New York/US
  • 2 Massachusetts General Hospital, Boston/US
  • 3 Massachusetts General Hospital, 02114 - Boston/US
  • 4 Brigham and Women's Hospital, Boston/US
  • 5 University of Virginia, Charlotesville/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 129P


The recommended treatment for T3 non-small cell lung cancer (NSCLC) presenting with separate tumor nodule(s) in the same lobe as the primary (“T3-Add”) includes surgical resection followed by adjuvant chemotherapy. This study sought to assess long-term survival of patients receiving adjuvant chemotherapy for T3-Add tumors across different tumor histologies.


Patients with T3-Add, N0-2, M0 NSCLC, after restaging based on AJCC 8th Edition TNM staging guidelines, in the National Cancer Database (NCDB) from 2010 to 2015 who underwent lobectomy with complete (R0) resection, without neoadjuvant therapy were included. Long-term overall survival was evaluated stratified by adjuvant chemotherapy status and histology (lung adenocarcinoma vs lung squamous cell carcinoma), using Kaplan-Meier analysis, Cox proportional hazards modeling, and propensity score matching on 11 common prognostic variables including comorbidities and clinical N status.


Of the 2,069 patients with T3-Add tumors who satisfied the study's inclusion criteria, 842 (40.7%) received adjuvant chemotherapy. Lung squamous cell histology was associated with significantly worse overall survival than lung adenocarcinoma histology (HR: 1.30, 95% CI: 1.09–1.56, p = 0.003). 41.7% (677/1,624) patients with adenocarcinoma and 37.1% (165/445) patients with squamous cell carcinoma received adjuvant chemotherapy. Individual propensity score-matched analyses stratified by histology were conducted comparing patients that did or did not receive adjuvant therapy. In the adenocarcinoma cohort (466 in each arm), use of adjuvant chemotherapy was not significantly associated with overall survival (66.3% [95% CI: 61.2–70.9] vs 63.8% [95% CI: 58.6–68.5], p = 0.24). However, for patients with lung squamous cell carcinoma (100 in each arm), adjuvant chemotherapy was associated with better 5-year overall survival (56.9% [95% CI: 44.0–67.8] vs 45.1% [95% CI: 33.5–56.1]).


The results of this national analysis support current guidelines that recommend adjuvant chemotherapy following surgery for T3 NSCLC presenting as a primary tumor with additional intrapulmonary nodule(s) in the same lobe for lung squamous cell carcinoma but not for lung adenocarcinoma.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.